A Multiallelic Molecular Beacon-Based Real-Time RT-PCR Assay for the Detection of SARS-CoV-2

Emerging infectious viruses have led to global advances in the development of specific and sensitive detection techniques. Viruses have an inherent potential to easily mutate, presenting major hurdles for diagnostics and requiring methods capable of detecting genetically diverse viral strains. One such infectious agent is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in December 2019 and has resulted in the global coronavirus disease 2019 (COVID-19) pandemic. This study presents a real-time reverse transcription PCR (RT-PCR) detection assay for SARS-CoV-2, taking into account its intrinsic polymorphic nature that arises due to genetic drift and recombination, as well as the possibility of continuous and multiple introductions of genetically nonidentical strains into the human population. This advance was achieved by using mismatch-tolerant molecular beacons designed to specifically detect the SARS-CoV-2 S, E, M, and N genes. These were applied to create a simple and reproducible real-time RT-PCR assay, which was validated using external quality control panels (QCMD: CVOP20, WHO: SARS-CoV-2-EQAP-01) and clinical samples. This assay was designed for high target detection accuracy and specificity and can also be readily adapted for the detection of other emerging and rapidly mutating pathogens.


Introduction
Infectious diseases caused by pathogenic agents are among the most prominent leading causes of death worldwide. In the last few decades alone, humanity has experienced the emergence and/or re-emergence of pathogens, which has led to epidemics and pandemics, such as those caused by human immunodeficiency virus (HIV), influenza, severe acute respiratory syndrome (SARS), and Ebola. Evidently, viral pathogens are more often than not the causative agents of emerging infections [1,2]. Currently, the world is facing yet another pandemic, which was initially identified as an outbreak of pneumonia cases of an unknown cause in December 2019 in Wuhan city, the capital of Hubei Province in China. This respiratory disease was named coronavirus disease 2019 (COVID- 19), after its causative agent, which was revealed to be a novel coronavirus named SARS coronavirus 2 (SARS-CoV-2) [3]. SARS-CoV-2 is the third zoonotic human coronavirus that can cause severe disease, with the other two being SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) [4][5][6][7].
As a member of the Coronaviridae family, SARS-CoV-2 has a positive-sense, singlestranded ribonucleic acid (RNA) genome of ∼ 30,000 base pairs (bp), the largest genome of all RNA viruses that infect humans. Through sequencing and phylogenetic studies, SARS-CoV-2 was classified in the genus Betacoronavirus along with SARS-CoV and MERS-CoV [8]. It has been discovered that the SARS-CoV-2 genome has 14 open reading frames (ORFs), with the first being ORF1ab, which encodes 15-16 nonstructural proteins (nsps) and mainly comprises the replicase/transcriptase complex that is important for viral replication [9]. Following ORF1ab, the four main structural proteins are encoded: spike (S), envelope (E), membrane (M), and nucleocapsid (N). These proteins are constituents of the coronavirus virion and have accessory functions in the life cycle of the virus [8,9]. The SARS-CoV-2 genome also encodes the accessory proteins 3ab, 6, 7ab, 8, 9bc, and 10, whose predicted functions are mostly based on sequence similarity with SARS-CoV homologs [9,10]. Consequently, several aspects of the SARS-CoV-2 genome, proteome, and clinical manifestations are still under investigation [11].
The information gained from studying previous coronaviruses has served as a basis for SARS-CoV-2 research [12]. Similar to previous coronaviruses, SARS-CoV-2 mainly causes respiratory illness outbreaks [7], and as such, patients infected with SARS-CoV-2 show symptoms of viral pneumonia, including coughing, breathing difficulties, fever and, in the most severe cases, bilateral lung infiltration. However, a wide range of clinical manifestations has been observed, and in some cases, patients exhibit neurological symptoms [13,14].
Due to the severity of SARS-CoV-2 infection, it is imperative that molecular detection assays be developed. These assays must be adaptable, specific, and sensitive, since this virus is spreading rapidly, continuously receiving evolutionary pressures from the host's immune system, antiviral drugs, vaccines, and transmission/replication within human populations of different genetic and environmental backgrounds [15][16][17]. SARS-CoV-2 has acquired dozens of mutations and has been classified into a myriad of lineages [18][19][20], highlighting the need to increase global efforts and improve detection strategies to account for the variability of the virus. However, current diagnostic methods can be limited in terms of sensitivity and specificity due to the polymorphic nature of SARS-CoV-2, and thus, there is room for improvement [21][22][23][24].
Therefore, in light of the rapid spread and continuous evolution of SARS-CoV-2, we developed a real-time reverse transcription polymerase chain reaction (real-time RT-PCR) assay utilizing mismatch-tolerant molecular beacons, which can detect this novel coronavirus [25]. The assay incorporates four beacons targeting the S, E, M, and N genes, in addition to an internal positive control (IPC) and synthetic RNA transcripts of the aforementioned gene targets that were used as positive controls. This assay was validated using external quality assessments (EQAs) from the World Health Organization (WHO) and Quality Control for Molecular Diagnostics (QCMD) and clinical samples on the premise of SARS-CoV-2 diagnostic surveillance performed at the University of Cyprus.

Molecular Beacon and Primer Design
The molecular beacons, primers, and target amplicons used for this assay were created de novo ( Table 1). The assay was designed to detect small regions (95-147 nucleotides) of the SARS-CoV-2 (GenBank accession number MN908947.3) S, N, M, and E genes ( Figure 1). Each oligonucleotide was designed using multiple sequence alignments from SARS-CoV and SARS-CoV-2 sequences acquired through the GenBank database (http://www.ncbi.nlm.nih.gov/GenBank, accessed on 26 February 2020): specifically, the pathogenic strains SARS-Urbani (AY278741), SARS-Tor2 (AY274119), and SARS-CoV-2 and the Italian SARS-CoV-2 isolate MT066156 ( Figure 2). Sequence alignments were performed using ClustalW [26] and Geneious ® 11.1.4 [27] and were used to identify genomic regions in the previously mentioned coronaviruses that were suitable for designing all oligonucleotides pertinent to this assay. The molecular beacons and primers were aimed to detect SARS-CoV-2 regardless of lineage. The molecular beacons and primers targeting the E gene were designed to identify all SARS-CoV and SARS-CoV-2 sequences used in the alignment, while the S, N, and M genes were used for discriminatory testing specific for SARS-CoV-2. A synthetic IPC was also designed using oligonucleotide sections of the aforementioned genes. The folding and structure of each molecular beacon along with their thermodynamic details were examined using the Mfold deoxyribonucleic acid (DNA) folding webtool [28]. Each molecular beacon was designed so that the stems were six nucleotides long, were complimentary to each other and had a high GC content. Furthermore, the molecular beacons of S, N, M, and E were labeled with the quencher N-[4-(4-dimethylamino)phenylazo]benzoic acid (DABCYL) at the 3 end and N-HEX-6-aminohexanol (HEX) fluorophore at the 5 end, except for the E gene, which was labeled with N-TET-6-aminohexanol (TET), and the IPC, which was labeled with 6-carboxy fluorescein (FAM). Imperative to the purposes of this assay was that the loop section of each molecular beacon, which acts as a probe and is complementary to the targeted gene fragment, was designed to be 24-26 nucleotides long, which constitutes the beacons as mismatch tolerant. Whereas, in contrast to allele discrimination, these longer loops are specific and form stable hybrids with their targets, yet their length allows them to be tolerant toward mismatches from mutations that may occur in the genome of SARS-CoV-2 due to recombination and genetic drift [29,30]. The molecular beacons were designed with a high GC content to prevent them from being in an open conformation during PCR in the absence of target. Analysis of the thermodynamic compatibilities of the primers and molecular beacons along with primer self-dimer and heterodimer formation (primer-primer and molecular beacon-primer) were analyzed using the Oligo Analyser tool (IDT, Integrated DNA Technology, Coralville, IA, USA). Through this analysis, the primer-primer and molecular beacon-primer thermodynamic compatibility was evaluated to ensure no cross hybridization between primers and beacons of different genes, since the oligonucleotides (molecular beacons and primers) were designed to have similar melting temperature profiles. It is important to note that in contrast to the molecular beacons, the primers were not designed to be mismatch tolerant, but they were specifically designed to detect SARS-CoV-2. The molecular beacons were synthesized by Biosearch Technologies (Risskov, Denmark), and the primers and other oligonucleotides were synthesized by Macrogen Europe (Amsterdam, The Netherlands) and Biosearch Technologies (Risskov, Denmark).

Internal Positive Control
An internal positive control was developed, which was a synthetic oligonucleotide designed as a mosaic of fragments of the S, E, M, and N genes ( Table 1). The IPC amplicon was designed so that it could be amplified by the forward primer for the S gene and the reverse primer for the E gene, while the molecular beacon target sequence was comprised of fragments of the M and N genes. The IPC was compared against the National Center for Biotechnology Information (NCBI) database [32] to ensure that the design was unique and did not recognize other sections of the SARS-CoV-2 genome or the human genome. The IPC was used as a reaction control and it was added during the real time RT-PCR stage.

Thermal Profiles of Molecular Beacons
Melting curve analysis was performed on a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) to assess the thermodynamic characteristics of the molecular beacons. To establish the optimal fluorescence, a variety of molecular beacon concentrations were tested. Ultimately, each reaction volume was 25 µL and consisted of 1.5 µL of MgCl 2 (50 mM), 2 µL of molecular beacon, 1 µL of a single-stranded oligonucleotide complementary to the target sequence (100 pmol/µL), and 20.5 µL of dH 2 O. To note, the different concentrations that were tested for the molecular beacons were 5, 7.5, and 10 pmol/µL, for a total of 10, 15, and 20 pmol per reaction. The PCR cycling conditions consisted of 1 cycle for 2 min at 95 • C, followed by 50 cycles split in two steps. The first step, during which data were collected, was at 80 • C for 30 s, decreasing by 1 • C per cycle, and the second step was at 80 • C for 10 s, decreasing by 1 • C per cycle. Fluorescence was measured at 535 nm for HEX, 521 nm for TET, and 495 nm for FAM, and the fluorescence was recorded at each cycle. Following the completion of the run, the fluorescence signal data were normalized and plotted.

RNA Transcripts
Synthetic RNA transcripts of each gene target amplicon were developed. These RNA transcripts were transcribed from DNA templates by in vitro transcription using a MEGAscript T7 transcription kit (Ambion, Houston, TX, USA) in accordance with the manufacturer's specifications. Specifically, to make the RNA transcripts of each gene target, DNA templates were amplified using PCR and forward primers ( Table 1) that encompassed the T7 RNA polymerase promoter recognition site (TAATACGACTCACTATAGG) at the 5 end. For the S, E, M, and N genes, DNA templates were generated using SARS-CoV-2 RNA (BetaCoV/Germany/BavPat1/2020 p.1" grown in cell culture (Charité, Berlin, European Virus Archive goes Global, EVAg)); thus, RT-PCR was performed to generate these templates. However, for the IPC, a single-stranded DNA template was used for the generation of the T7-IPC DNA template.
The volume of each PCR to generate DNA templates was 50 µL, which contained The RNA transcripts were purified using NucAway™ Spin Columns Mix (Thermo Fisher Scientific, Waltham, MA, USA). The eluates were then quantified using a NanoDrop ® ND-1000 (NanoDrop Technologies, Wilmington, DE, USA). To ensure that there were no traces of DNA template in the RNA transcripts, real-time PCR was performed. Then, realtime RT-PCR was performed to check that the RNA transcripts were properly amplified (as indicated below).

Real-Time RT-PCR: Uniplex and Duplex Reactions
The assay was designed to be used in uniplex and in duplex when each target is run with the IPC.  Table 1. The reverse transcription cycling conditions consisted of 1 cycle at 25 • C for 2 min, followed by 1 cycle at 53 • C for 10 min and 1 cycle at 95 • C for 2 min. This was followed by 5 cycles at 95 • C for 3 s and 53 • C for 30 s. Finally, there were 35 cycles at 95 • C for 3 s and 53 • C for 30 s, when data collection took place. In these runs, no-template controls (NTCs) (dH 2 O) were also added as negative controls, while synthetic RNA transcripts (10 3 and 10 6 copies per µL) and SARS-CoV-2 RNA (10 3 copies per µL) (BetaCoV/Germany/BavPat1/2020 p.1" grown in cell culture (Charité, Berlin, EVAg)) were used as positive controls. The controls were assayed in duplicate for each reaction. Following the completion of the run, the fluorescence signal data were normalized and plotted.
For duplex real-time RT-PCR, the protocol was adapted to account for the increased number of primers and molecular beacons. This protocol was specifically performed for the S, M, and N genes, and each of the genes was amplified with the IPC in the same reaction. The final volume of the reaction was increased to 40 µL, and each contained the following: 10 µL of SARS-CoV-2 RNA at 10 6 copies/µL (BetaCoV/Germany/BavPat1/2020 p.1" grown in cell culture (Charité, Berlin, EVAg)) or RNA transcripts, 10 µL of IPC target at 10 6 copies/µL, 7.5 µL of 4× TaqPath™ 1-Step Multiplex Master Mix, 3 µL of the two molecular beacons (5 pmol/µL) in each reaction, 1.5 µL of each primer at 20 pmol/µL, and 0.5 µL of dH 2 O. Notably, for the S-IPC duplex reaction, a new forward primer was designed for the S-gene target, (F) 22,157 (GGTTATTTTAAAATATATTCTAAGCACACGC,22,187). For validation of the duplex reactions, a NTC (dH 2 O) was added as a negative control. The targets were also run in uniplex reactions to compare the fluorescence signal between the uniplex and duplex. The cycling conditions remained the same as those in the uniplex real-time RT-PCR. The fluorophores FAM for IPC and HEX for S, M, and N were selected specifically because their excitation wavelengths have little-to-no overlap in their emission spectra. Following the completion of the run, the fluorescence signal data were normalized and plotted.

Validation and Clinical Samples
Validation was accomplished by testing the assay on two external quality assessment (EQA) programs. The first EQA program for the detection of SARS-CoV-2 was hosted by the WHO (WHO SARS-CoV-2 EQAP (2020)). This program provided a panel of five samples of dried, extracted coronavirus RNA (including SARS-CoV-2 RNA in different dilutions and RNA from other currently circulating human coronavirus RNA) as well as a positive control SARS-CoV-2 RNA sample. The second program was from QCMD (QCMD 2020 Coronavirus Outbreak Preparedness EQA Pilot Study), which provided a total of eight samples in transport medium. These programs were designed to evaluate a laboratory's ability to detect SARS-CoV-2 (COVID-19) using routine molecular methods, and the results were reported during June 2020.
The assay was further validated under the premise of diagnostic surveillance testing that was performed for students and personnel of the University of Cyprus from September 2020-January 2021 as part of the university's SARS-CoV-2 surveillance. Nasopharyngeal samples were collected using nasopharyngeal swabs (Biocomma, Shenzhen, China), were placed in tubes with preservation medium (Biocomma, Shenzhen, China), and stored in the fridge (4 • C) for a maximum of 4 h before RNA was extracted. RNA extraction was performed using a QIAmp Viral RNA Mini Kit (Qiagen, Hilden, Germany) and a QIAcube Connect machine (Qiagen, Hilden, Germany) in accordance with the manufacturer's specifications. Notably, samples were collected using the pooling method, with an average of five samples per pool, and study subjects from positive pools were tested again using new individual samples. Bioethical approval was received by the Cyprus National Bioethics Committee (EEBK EΠ 2020.01.192), and to ensure patient anonymity, all samples were double coded; thus, connections could not be made between the samples and the corresponding study subjects. The collection, processing, and use of samples was in compliance with the rules and regulations of the Cyprus National Bioethics Committee.

Molecular Beacon Thermal Denaturation Profiles
For each molecular beacon, the fluorescence for the beacon-target hybrids and for the beacon without target was plotted against temperature to ascertain their thermal characteristics, as well as to identify the appropriate melting temperature for the molecular beacons to hybridize with their targets (Figure 3). As shown in Figure 3, in the absence of the target, the molecular beacons alone displayed a melting temperature of approximately 60 • C, while the largest difference in fluorescence signal between molecular beacons alone and beacon-target hybrids occurred from 35-55 • C. Taking into account the higher fluorescence signal of beacon-target hybrids vs that of beacon alone and the melting temperatures of the primers used in this assay (Table 1), a temperature of 53 • C was selected for the real-time RT-PCRs. Additionally, the optimal concentration that was established for the molecular beacons was 15 pmol per reaction.

Real-Time RT-PCR Validation and Testing
The assay was first tested using SARS-CoV-2 RNA (BetaCoV/Germany/BavPat1/2020 p.1" grown in cell culture (Charité, Berlin, Germany, EVAg)) ( Figure 4, Table 2). As shown in Figure 4, all target regions were successfully amplified, and the molecular beacons were able to bind to their targets and properly fluoresce, while in the absence of the target (black dots), there was no amplification or fluorescence signal, as expected. Furthermore, for all genes and the IPC, the signal exceeded the threshold at approximately the 32nd-35th cycle. In Figure 5, the duplex reactions of each of the S, M, and N genes in combination with the IPC can be observed. All targets were successfully amplified, and the molecular beacons fluoresced, indicating that there was no cross hybridization and that the duplex reactions did not hinder the results. In the absence of the target, there was no amplification and no fluorescence signal (black dots). The IPC exceeded the threshold at the 19th-20th cycle, while the S, M, and N beacons exceeded the threshold at the 20th-23rd cycle.     Following testing on purified SARS-CoV-2 RNA, two EQAs were used for the validation of the assay, one from the WHO (WHO SARS-CoV-2 EQAP (2020)) and one from QCMD (QCMD 2020 Coronavirus Outbreak Preparedness EQA Pilot Study) ( Table 2). For the WHO EQA, the assay successfully identified all blinded samples as well as the positive control. This assay displayed the sensitivity needed to identify the SARS-CoV-2 RNA samples included in the WHO EQA at low, medium, and high concentrations (7.11 × 10 4 , 7.42 × 10 5 and 1.14 × 10 6 copies/mL), while it indicated sufficient specificity since it did not identify the negative control and the human coronavirus (hCoV) OC43 RNA. For the QCMD EQA, the assay successfully identified all blinded samples, with SARS-CoV-2 concentrations ranging as low as~2 × 10 2 copies/mL and as high as~2 × 10 5 copies/mL. Similar to the WHO panel, the assay showed no amplification signal and did not identify as positive hCoV NL63, hCoV OC43 or the negative control in the QCMD EQA panel. Based on the results, the 15 samples included in Table 2, the purified SARS-CoV-2 RNA, and the samples of the two EQA panels, the assay is sensitive enough to detect SARS-CoV-2 in samples containing varying concentrations and specific enough to discriminate SARS-CoV-2 from other human coronaviruses, displaying 100% detection ability and 100% specificity.
For the SARS-CoV-2 surveillance testing performed for students and personnel at the University of Cyprus from September 2020-January 2021, 534 pooled samples were collected, with an average of 5 samples per pool, for a total of 2231 study subjects tested using this assay. From this testing we had identified 22 positive pools and the study subjects from pools that were identified as positive were called in for resampling, and 15 were identified as positive through individual testing using this assay, and an additional one was identified as positive through rapid testing. Importantly, not all targets were required to be performed at once, samples were routinely tested by one target and SARS-CoV-2 positivity was confirmed by a second target, provided the negative and positive controls were correct. The positive controls were in concentrations of 10 3 copies per µL and 10 6 copies per µL, were utilized in every run, and the average threshold cycle was 31.7 ± 1.7, and 21.6 ± 1.1 respectively.

Discussion
The past SARS-CoV epidemic left the future possibility of re-emergence or emergence of other coronaviruses as highly probable [25]. This fact stimulated vigilance toward these viruses and provided us with the basis to develop diagnostic tests faster for other viruses, such as the current SARS-CoV-2 pandemic. The molecular beacon-based real-time RT-PCR assay presented here was originally developed for SARS-CoV by our laboratory [25] (US Patent No. 7,709,188 B2, issued 4 May 2010) and was designed with the capability for adaptation for such viruses and polymorphisms that may arise during the course of their epidemics/pandemics. This rapid and accurate assay, which was modified and further developed for SARS-CoV-2 detection, is an essential tool for the assessment and optimization of disease prevention measures established to safeguard the population, and it can be modified for other infectious agents that harbor a capacity for mutations and constitute a threat to public health.
The sequence identity between SARS-CoV and SARS-CoV-2 has been reported to be 79.5%, and despite this high degree of similarity, there are distinct differences between their genomes, some of which relate to their transmissibility and clinical outcomes [33]. The bioinformatic analysis performed for this study, specifically the multiple sequence alignment, elucidated regions of higher and lower similarity within the structural genes S, E, M, and N between SARS-CoV (Urbani and Tor2) and SARS-CoV-2 (MN908947.3 and MT066156) used for this study ( Figure 2). Thus, the region in the E gene that was selected as a target serves as a screening part of the assay because it is conserved among these SARS viruses, and even within SARS-CoV-2, 98.8% of the E protein of SARS-CoV-2 strains worldwide is highly conserved [34]. Similarly, the M protein has also been reported to have a slower rate of evolution and is also highly conserved [35,36]; however, along with the S and N proteins, which tend to evolve faster [36], regions with higher variability were selected for this assay to discriminate between SARS viruses ( Figure 2). It is important to note that numerous mutations have already been reported. Taking the S gene as an example, there are at least 8 mutations/deletions in all variants of concern [37], which serve as evidence of the current existing variability that can very well impact current testing methods and show the potential for the accumulation of additional mutations in the near future.
It is therefore important for testing methods to account for the variability in SARS-CoV-2, which arises despite its nsp 14 proofreading capabilities [38]. Nonetheless, SARS-CoV-2 receives evolutionary pressures, and as such, numerous lineages are generated that encompass different sets of mutations and deletions [39]. Reports have already shown that these mutations and deletions compromise SARS-CoV-2 detection assays [21][22][23][24], thereby highlighting the urgent need for the development of screening assays specifically designed to accommodate the polymorphic nature of the virus. A strength of the assay presented in this study has addressed this issue through mismatch-tolerant ("sloppy") molecular beacon technology [29], which allows for the detection of polymorphisms that may occur in the target sequence. Importantly, the specificity of the beacons is not compromised by a small number mismatched base pairs since the beacon-target duplex is long enough to account for these unexpected polymorphisms [30]. Furthermore, the sensitivity and specificity of the assay is increased since four target regions were selected on four different genes, thereby maximizing the probability of detecting SARS-CoV-2 and minimizing the likelihood of false positive and false negative results. The latter is further supported by both the IPC designed for this assay and the RNA transcript positive controls of each gene.
The present assay exhibited 100% specificity and sensitivity when tested with EQA samples from the WHO and QCMD. It was able to distinguish and identify SARS-CoV-2 from other human coronaviruses, even at borderline concentrations as low as~2 × 10 2 copies/mL. However, to improve upon the limitations of this assay, and in order for it to move to clinical or commercial settings, it would require it to be compared with other already available methods [40], as well as a larger cohort to enable more detailed measurements of the limit of detection and precision of the assay. Furthermore, it is important to keep in mind that the pooling method that was utilized for the validation of the assay with the public diagnostic surveillance at the University of Cyprus would be applicable for low prevalence settings.
Nonetheless, during the testing of this assay at the University of Cyprus for public diagnostic surveillance testing, 16 individual samples were identified as corresponding to SARS-CoV-2 infection out of the 534 pooled nasopharyngeal samples, which were later sequenced as part of a publication regarding a molecular epidemiological study of SARS-CoV-2 infection in Cyprus [41]. In this separate publication, the majority of these 16 samples were classified within the B.1.258 lineage, while the lineages B.1.177 and B.1.1.29 were also identified [41]. Yet, even though certain mutations/deletions, as mentioned above, have been reported to compromise SARS-CoV-2 real-time PCR testing methods, such as ∆H69/V70 [21], which was also found in the B.1.258 lineage, the present assay was unaffected since it did not target those mutated regions of the genome. Nevertheless, the assay was limited by the SARS-CoV-2 lineages that were circulating [41] during the period of the public diagnostic surveillance, and as such, the assay was not applied to a more diverse set of lineages. Moreover, as the pandemic progresses and SARS-CoV-2 is evolving, the assay must be tested with samples from new variants, such as the Delta variant of concern, which was not available during the development and validation of the assay (EQAs June 2020 and public diagnostic surveillance samples September 2020-January 2021). Hence, vigilance must be exercised, and we are regularly checking publicly available genomes from the GISAID database (https://www.gisaid.org/, accessed on 4 October 2021) [42], to ascertain that the number of accumulated mutations does not impact the primers (which are not mismatch tolerant), and is not exceeding the tolerance capabilities of the molecular beacons, ensuring that they can still bind to their targeted regions and consequently detect SARS-CoV-2. Nonetheless, another benefit of the design of this assay is that it provides the advantage of being easily and rapidly adaptable if the above scenario occurs.
Overall, we present an accurate and reliable uniplex real-time RT-PCR assay, which can also incorporate an IPC. This assay is based on molecular beacons specifically designed to allow for mutations that may arise from the evolutionary pressures that SARS-CoV-2 experiences. This study lays down the foundational work and presents the methodology relevant for this assay to be extrapolated for commercialization and clinical testing at a later stage. This assay offers a fast and efficient way to diagnose SARS-CoV-2 and can serve as a valuable and easily adaptable detection method for current and future mutating infectious agents.  Institutional Review Board Statement: The nasopharyngeal samples from study subjects were analyzed after receiving approval by the Cyprus National Bioethics Committee (EEBK EΠ 2020.01.192). The samples were coded with a laboratory or patient identification number, and then were further coded with a new laboratory identification number to ensure no connection of the samples to the corresponding study subjects could be made. The collection and use of the samples were in accordance with the relevant guidelines and regulations of the Cyprus National Bioethics Committee. Informed Consent Statement: Patient consent was waived by the Cyprus National Bioethics Committee (EEBK EΠ 2020.01.192) due to the anonymity and double-coding of the samples.

Data Availability Statement:
The results will be available upon request from the corresponding author.